TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01646645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-pp65 CTLs
Description: Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
Study: NCT03362099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Tartrate or bupropion
Description: the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
Study: NCT02944474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat
Description: Capsule for oral administration containing lucerastat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching lucerastat capsules
Study: NCT03274401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zenicor intermittent ECG device
Description: At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5 day ECG patch
Description: Selection of device for monitoring clinicians' choice
Study: NCT02275650

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: nbUVB
Description: 2 SED nbUVB exposure will be given every other week
Study: NCT02659306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
Study: NCT02263794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bronchial Thermoplasty
Description: Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image Guided Bronchial Thermoplasty
Description: Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
Study: NCT00592839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCE-B
Description: 0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCE-B
Description: 0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for 0.3 mg and 0.625 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for 0.3 mg and 0.625 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for 0.3 mg and 0.625 mg tablets
Study: NCT04496544

Intervention type: OTHER
Intervention: Retrospective data collection
Description: No intervention; retrospective data collection

Intervention type: OTHER
Intervention: Retrospective data collection
Description: No intervention; retrospective data collection
Study: NCT00075179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide (Natrecor)
Description: Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Heart Catheterization
Description: Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
Study: NCT01760330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01223989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypocaloric diet balanced + nutrition education + ruled physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet balanced + nutrition education + ruled physical activity
Study: NCT03933189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy modalities to treat chronic pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy modalities to treat chronic pain
Study: NCT00372125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin SimpleXx
Description: 0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norditropin SimpleXx
Description: 0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
Study: NCT03828357

Intervention type: OTHER
Intervention: Study MRI scan
Description: At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.

Intervention type: OTHER
Intervention: Study MRI scan
Description: At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.

Intervention type: OTHER
Intervention: Study MRI scan
Description: At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.

Intervention type: OTHER
Intervention: Study MRI scan
Description: At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
Study: NCT02041286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karajishi Contour Investigational BG Monitoring System
Description: Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
Study: NCT03372811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC cream
Description: A well-characterized botanical drug for topical treatment of psoriasis vulgaris

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT03621488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Efficacy of Behavioral Self-Activation with virtual reality
Description: Efficacy of Behavioral Self-Activation with virtual reality

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Efficacy of Behavioral Self-Activation without virtual reality
Description: Efficacy of Behavioral Self-Activation without virtual reality
Study: NCT01943292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Study: NCT00106392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT04024332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 25 mg; administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 25 mg; administered orally
Study: NCT04051385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal treatment
Description: SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid and serum collection
Description: GCF with filter paper using the intracrevicular method and serum collection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid and serum collection
Description: GCF with filter paper using the intracrevicular method and serum collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid and serum collection
Description: GCF with filter paper using the intracrevicular method and serum collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gingival crevicular fluid and serum collection
Description: GCF with filter paper using the intracrevicular method and serum collection
Study: NCT03248193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concomitant limb cryocompression and scalp cooling
Description: Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concomitant limb cryocompression and scalp cooling
Description: The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects.
Study: NCT02804698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education intervention
Description: 13-week educational and physical activity intervention
Study: NCT02829892

Intervention type: DEVICE
Group type: OTHER
Intervention: Light therapy
Description: 14-days exposure with an innovative ambient light
Study: NCT04767178

Intervention type: DRUG
Intervention: Ibuprofen (Sanofi, Istanbul, Turkey)
Description: Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.

Intervention type: DRUG
Intervention: Paracetamol (GlaxoSmithKline, Istanbul, Turkey)
Description: Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
Study: NCT03660228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peri-Transfusion QOL Assessment
Description: Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
Study: NCT04182321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin & Entecavir
Description: Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Study: NCT00168688

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi micronutrient supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MN1
Description: Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MN2
Description: Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
Study: NCT01514812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral - modified release formulation of YM150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral - modified release formulation of YM150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: oral
Study: NCT02326376

Intervention type: DRUG
Intervention: anakinra (Kineret)
Study: NCT01732250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
Study: NCT04841031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET Treatment
Description: Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.

Intervention type: OTHER
Group type: OTHER
Intervention: Alternative Intervention
Description: Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
Study: NCT01509833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: Administration of rFSH for ovarian stimulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: Administration of late follicular low dose hCG(100IU) for ovarian stimulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
Study: NCT02579850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 + Ultibro matched placebo
Description: Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultibro + CHF 5993 matched placebo
Description: Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central spirometry
Description: Central spirometry to assess forced expiratory volume at one second and forced vital capacity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central spirometry
Description: Central spirometry to assess forced expiratory volume at one second and forced vital capacity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD assessment test
Description: COPD assessment test (CAT) at visit 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPD assessment test
Description: COPD assessment test (CAT) at visit 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local laboratory Assessments
Description: ECG + Standard Haematology and Biochemistry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local laboratory Assessments
Description: ECG + Standard Haematology and Biochemistry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saint George's Respiratory Questionnaire
Description: Saint George's Respiratory Questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saint George's Respiratory Questionnaire
Description: Saint George's Respiratory Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXACT-pro questionnaire
Description: daily from randomization (Visit 2) to end of study (Visit 7)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EXACT-pro questionnaire
Description: daily from randomization (Visit 2) to end of study (Visit 7)
Study: NCT01431833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral single dose 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral single dose 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Oral single dose 200 mg
Study: NCT03244345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-measurement scale of sensitivity to stress/emotion
Description: Patient will answer self-questionner on Depression
Study: NCT01711177

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost
Description: Travatan Z is administered to newly diagnosed glaucoma patient
Study: NCT01558830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranolazine
Description: ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
Study: NCT01339338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warming the contrast media
Description: warm the contrast media with 37℃ water-bathing
Study: NCT01558830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
Study: NCT03017950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 + D086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 + D086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 + D086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 + D086
Study: NCT01252017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: nilotinib (200mg/tab) 1 tab everyday
Study: NCT01662258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-Care diagnostic laboratory test
Description: All POC tests are FDA-cleared.
Study: NCT02823288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonke CHANGE intervention
Description: The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability.